Classification and treatment of radiation maculopathy.

Hdl Handle:
http://hdl.handle.net/10147/207754
Title:
Classification and treatment of radiation maculopathy.
Authors:
Horgan, Noel; Shields, Carol L; Mashayekhi, Arman; Shields, Jerry A
Affiliation:
Royal Victoria Eye and Ear Hospital, Dublin, Ireland. Noel.Horgan@rveeh.ie
Citation:
Curr Opin Ophthalmol. 2010 May;21(3):233-8.
Journal:
Current opinion in ophthalmology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207754
DOI:
10.1097/ICU.0b013e3283386687
PubMed ID:
20393294
Abstract:
PURPOSE OF REVIEW: Radiation maculopathy is a sight-limiting consequence of radiotherapy in the management of uveal melanoma and other intraocular tumors. In this review, we consider clinical, fluorescein angiographic and optical coherence tomographic findings, propose a classification for radiation maculopathy and discuss the management of this condition. RECENT FINDINGS: Radiation macular edema (RME) can be classified by optical coherence tomography into noncystoid or cystoid edema, with foveolar or extrafoveolar involvement. Optical coherence tomographic grading of RME has been found to correlate with visual acuity. Focal argon laser might have some limited benefit in the treatment of RME. Intravitreal triamcinolone and intravitreal antivascular endothelial growth factor agents can be of short-term benefit in the treatment of RME. In a randomized controlled trial, periocular triamcinolone significantly reduced rates of RME and vision loss up to 18 months following plaque radiotherapy for uveal melanoma. SUMMARY: Currently, there is no proven treatment for established RME, though periocular triamcinolone has been shown to have a preventive benefit. An accepted classification system for radiation maculopathy would be of benefit in planning and comparing future treatment trials.
Language:
eng
MeSH:
Fluorescein Angiography; Humans; Radiation Injuries/*classification/etiology/*therapy; Radiotherapy/*adverse effects; Retina/*radiation effects; Retinal Diseases/*classification/etiology/*therapy; Tomography, Optical Coherence; Uveal Neoplasms/radiotherapy
ISSN:
1531-7021 (Electronic); 1040-8738 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorHorgan, Noelen_GB
dc.contributor.authorShields, Carol Len_GB
dc.contributor.authorMashayekhi, Armanen_GB
dc.contributor.authorShields, Jerry Aen_GB
dc.date.accessioned2012-02-01T10:40:14Z-
dc.date.available2012-02-01T10:40:14Z-
dc.date.issued2012-02-01T10:40:14Z-
dc.identifier.citationCurr Opin Ophthalmol. 2010 May;21(3):233-8.en_GB
dc.identifier.issn1531-7021 (Electronic)en_GB
dc.identifier.issn1040-8738 (Linking)en_GB
dc.identifier.pmid20393294en_GB
dc.identifier.doi10.1097/ICU.0b013e3283386687en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207754-
dc.description.abstractPURPOSE OF REVIEW: Radiation maculopathy is a sight-limiting consequence of radiotherapy in the management of uveal melanoma and other intraocular tumors. In this review, we consider clinical, fluorescein angiographic and optical coherence tomographic findings, propose a classification for radiation maculopathy and discuss the management of this condition. RECENT FINDINGS: Radiation macular edema (RME) can be classified by optical coherence tomography into noncystoid or cystoid edema, with foveolar or extrafoveolar involvement. Optical coherence tomographic grading of RME has been found to correlate with visual acuity. Focal argon laser might have some limited benefit in the treatment of RME. Intravitreal triamcinolone and intravitreal antivascular endothelial growth factor agents can be of short-term benefit in the treatment of RME. In a randomized controlled trial, periocular triamcinolone significantly reduced rates of RME and vision loss up to 18 months following plaque radiotherapy for uveal melanoma. SUMMARY: Currently, there is no proven treatment for established RME, though periocular triamcinolone has been shown to have a preventive benefit. An accepted classification system for radiation maculopathy would be of benefit in planning and comparing future treatment trials.en_GB
dc.language.isoengen_GB
dc.subject.meshFluorescein Angiographyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshRadiation Injuries/*classification/etiology/*therapyen_GB
dc.subject.meshRadiotherapy/*adverse effectsen_GB
dc.subject.meshRetina/*radiation effectsen_GB
dc.subject.meshRetinal Diseases/*classification/etiology/*therapyen_GB
dc.subject.meshTomography, Optical Coherenceen_GB
dc.subject.meshUveal Neoplasms/radiotherapyen_GB
dc.titleClassification and treatment of radiation maculopathy.en_GB
dc.contributor.departmentRoyal Victoria Eye and Ear Hospital, Dublin, Ireland. Noel.Horgan@rveeh.ieen_GB
dc.identifier.journalCurrent opinion in ophthalmologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.